DVT/PE Awareness Study

NBCA DVT/PE Online Awareness Survey Results

The National Blood Clot Alliance conducted the first ever DVT/PE awareness survey among hospital patients, healthcare providers and the general public uncovering major awareness gaps. NBCA’s DVT/PE Awareness Survey was conducted by the national survey firm USA/Direct, Inc.

Study results have been presented at various healthcare provider meetings including the Society of Hospital Medicine, National Association of Orthopedic Nurses, American Academy of Family Physicians, American Society of Clinical Oncology and the American Public Health Association. The major study results are  below.

DVT/PE Awareness is Low Among Cancer Patients

Despite being at increased risk for deep vein thrombosis (DVT) and pulmonary embolism (PE), most cancer patients are not aware of the terms DVT and PE.Compared to oncology inpatients, DVT/PE prophylaxis is utilized much less frequently among oncology outpatients, according to NBCA’s DVT/PE Awareness Survey data.

Study Results >>>

Gaps in DVT/PE Prophylaxis Among Hospitalized Patients

Data from NBCA’s online survey of 500 patients who had been hospitalized for >3 days, show that less than one-third of respondents report DVT prophylaxis with either an anticoagulant pill or anticoagulant injection, even though more than 40% of them report that they had a family member who previously had a blood clot in the leg or lung, and 15% say they had a personal history of a blood clot in the leg or lung.

Study Results >>>

DVT/PE Awareness Among At-Risk THA/TKA Patients is Low

Therapeutic barriers perceived by total hip arthroplasty (THA) and total knee arthroplasty (TKA) surgeons impact their use of anticoagulation therapies in the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) among THA/TKA patients, and, despite evidence-based guidelines, DVT/PE prophylaxis practices vary widely,according to survey results.

Study Results >>>

The NBCA DVT/PE Awareness Survey was made possible by a grant from Ortho-McNeil™, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Current News

Introducing the NBCA Advocacy Institute

To put an end to the 100,000 deaths each year to blood clots, the National Blood Clot Alliance is accelerating…

NBCA Journal Club Convenes to Discuss Antithrombin Therapy

Launched last year, the NBCA Journal Club highlights groundbreaking research in thrombosis and thrombophilia and features a manuscript author as…